Nearly half of India's 10,000 drug manufacturing units might not meet the 2025 deadline for upgrading to revised Schedule M standards, risking closure. Currently, only 2,000 comply with good manufacturing practices. The industry seeks a two-year extension for improvements, but the government hasn't announced one yet. Audits and inspections may begin soon.
